Unresectable or metastatic hormone receptor-positive, HER2-negative (lHC 0, lHC1+ or lHC2+/lSH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.